FINWIRES · TerminalLIVE
FINWIRES

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

By

Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.

The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.

The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.

An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

Related Articles

Asia

Sunstone Metals Says Ecuador Gold Project Scoping Study Finds Initial 23-Year Mine Life

Sunstone Metals (ASX:STM) said a scoping study for its Bramaderos gold copper project in Ecuador has outlined an initial 23-year mine life producing 135,000 gold equivalent ounces per year for the first eight years, according to a Tuesday Australian bourse filing.The company said the study returned a post-tax net present value of $900 million at a gold price of $3,500 per ounce, with an all-in sustaining cost (AISC) averaging $1,499 per ounce after credits.Sunstone Metals said the operation is a conventional single open pit feeding a 10-million-tonne-per-year plant at a life-of-mine strip ratio of 1.4, with capital payback estimated at 34 months at $3,500 per ounce gold and 19 months at spot price.The company said potential for significant growth in inventory could underpin a possible stage 2 expansion.

ASX:STM
Asia

Bank of Maharashtra's Consolidated Profit Grows in Fiscal Q4

Bank of Maharashtra's (NSE:MAHABANK, BOM:532525) consolidated net profit rose to 20.4 billion Indian rupees in the fiscal fourth quarter ended March 31, from 15.0 billion rupees a year ago.Earnings per share climbed to 2.66 rupees from 1.95 rupees a year earlier, the bank said in a filing to the Indian stock exchanges on Monday.Interest earned by the lender in fiscal Q4 increased to 77.6 billion rupees from 67.3 billion rupees a year ago.The bank's board recommended a final dividend of 1.20 rupees per equity share of 10 rupees each for the financial year ended March 31.

BOM:532525NSE:MAHABANK
Asia

Ever Sunshine Services' Profit Falls 9% in 2025

Ever Sunshine Services (HKG:1995) posted a profit attributable to owners of 437.4 million yuan for 2025, down 8.5% from 478.0 million yuan a year earlier, according to its 2025 annual report released Monday.The residential property manager's shares were down nearly 2% in Tuesday morning trade.Earnings per share came in at 0.2530 yuan, compared with 0.2758 yuan in the prior year.Revenue rose slightly to 6.87 billion yuan from 6.84 billion yuan in 2024.The board recommended a final dividend of HK$0.0735 per share and a special dividend of HK$0.0294 per share.

HKG:1995